Systematic identification of signaling pathways with potential to confer anticancer drug resistance

BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact

(2014) H. Rizos et al.   CLINICAL CANCER RESEARCH

A Notch for Noncoding RNA in Melanoma

(2014) Levi A. Garraway   NEW ENGLAND JOURNAL OF MEDICINE

ColonyArea: An ImageJ Plugin to Automatically Quantify Colony Formation in Clonogenic Assays

(2014) Camilo Guzmán et al.   PLoS One

A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors

(2014) D. J. Konieczkowski et al.   Cancer Discovery

miR-146a promotes the initiation and progression of melanoma by activating Notch signaling

(2014) Matteo Forloni et al.   eLife

BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma

(2013) D. T. Frederick et al.   CLINICAL CANCER RESEARCH

Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma

(2013) Kieron Dunleavy et al.   NEW ENGLAND JOURNAL OF MEDICINE

A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop

(2013) K E Ware et al.   Oncogenesis

Converting Cancer Therapies into Cures: Lessons from Infectious Diseases

(2012) Michael S. Glickman et al.   CELL

BRAF Inhibitors for the Treatment of Metastatic Melanoma: Clinical Trials and Mechanisms of Resistance

(2012) A. M. Alcala et al.   CLINICAL CANCER RESEARCH

A Detailed Mammosphere Assay Protocol for the Quantification of Breast Stem Cell Activity

(2012) Frances L. Shaw et al.   JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA

Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation

(2012) Jennifer Landsberg et al.   NATURE

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

(2012) Ravid Straussman et al.   NATURE

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

(2012) Timothy R. Wilson et al.   NATURE

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

MicroSCALE Screening Reveals Genetic Modifiers of Therapeutic Response in Melanoma

(2012) K. C. Wood et al.   Science Signaling

Resistance to HER2-directed antibodies and tyrosine kinase inhibitors

(2011) Joan T. Garrett et al.   CANCER BIOLOGY & THERAPY

Mutant BRAF Melanomas—Dependence and Resistance

(2011) Poulikos I. Poulikakos et al.   CANCER CELL

Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status

(2011) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

Functional genomics reveal that the serine synthesis pathway is essential in breast cancer

(2011) Richard Possemato et al.   NATURE

A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer

(2011) Markus K Muellner et al.   Nature Chemical Biology

A public genome-scale lentiviral expression library of human ORFs

(2011) Xiaoping Yang et al.   NATURE METHODS

Notch1 regulates the expression of the multidrug resistance gene ABCC1/MRP1 in cultured cancer cells

(2011) S. Cho et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Heterogeneous Phenotype of Human Melanoma Cells with In Vitro and In Vivo Features of Tumor-Initiating Cells

(2010) Michela Perego et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

(2010) Cory M. Johannessen et al.   NATURE

PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer

(2010) S. Loi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Preclinical Profile of a Potent  -Secretase Inhibitor Targeting Notch Signaling with In vivo Efficacy and Pharmacodynamic Properties

(2009) L. Luistro et al.   CANCER RESEARCH

Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening

(2009) Piyush B. Gupta et al.   CELL

The basics of epithelial-mesenchymal transition

(2009) Raghu Kalluri et al.   JOURNAL OF CLINICAL INVESTIGATION

MEK1 mutations confer resistance to MEK and B-RAF inhibition

(2009) C. M. Emery et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen

(2008) Sherene Loi et al.   BMC GENOMICS

Modeling Genomic Diversity and Tumor Dependency in Malignant Melanoma

(2008) W. M. Lin et al.   CANCER RESEARCH

Cross-talk between Notch and the Estrogen Receptor in Breast Cancer Suggests Novel Therapeutic Approaches

(2008) P. Rizzo et al.   CANCER RESEARCH